Vesper Medical will further expand Philips’ portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
It is a novel oral NLRP3 inflammasome inhibitor
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
The company will donate 5000 nebulizers to primary health care centres in rural India
The company is focused on the development of novel treatments for RNA viruses
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated
